#arthritis therapies

[pharmanucleus1]

Global Osteoarthritis Market: Trends, Treatment, and Projections 2030

Report Summary 

In 2023, the worldwide osteoarthritis market was valued at USD 7.40 billion and is predicted to increase at an 8.5% CAGR during the forecast period 2023-2030. Both the introduction of analgesic drugs and the development of imaging diagnostics based on radiographic characteristics are stimulating market growth. Increased expenditure on healthcare infrastructure and expanding investments in research and development (R&D) efforts to bring novel diagnostics and biomarkers are also driving the market. 

Osteoarthritis (OA) is a group of disorders that affect the joints of the knees, hips, fingers, foot, back, shoulders, and neck. It is distinguished by the gradual degeneration of the cartilage in these joints. Stiffness, edoema, discomfort, persistent pain, loss of flexibility, a grating sensation, bone spurs, and sleep interruptions are all common symptoms of OA. 

Click here for full report:

Medical examination, X-rays, arthroscopy, joint fluid analysis, lab testing, and magnetic resonance imaging (MRI) scans can all be used to diagnose it. Depending on the outcomes, different medications and surgical techniques are prescribed to treat the disease's signs and symptoms. There are presently alternative medicines, physical therapy, and supporting devices on the market to relieve pain and improve joint function. 

Sedentary lifestyles, poor eating habits, and increasing weight and blood sugar levels make people more susceptible to develop OA. This is one of the primary driving drivers for market development, combined with an ageing population that is more susceptible to such disorders. Furthermore, the ease of access to MRI scans is a key growth-promoting factor. 

The COVID-19 outbreak is predicted to have only a minimal influence on the osteoarthritis therapy industry. Corticosteroids are being used less often in many medicine types. Although there is no evidence that corticosteroid injections significantly increase the risk of infection, the immune system may be less active for a few weeks following surgery. 

Even though the risk is extremely minimal, it should be taken into account before starting with the procedure. It should be noted that the World Health Organisation cautioned against the use of systemic corticosteroids in one of its guidelines for treating severe acute respiratory infections caused by coronavirus. 

Industry Dynamics 

Growth Drivers:  

Increased government investment on cell-based research, as well as the increasing use of opioids, are driving market expansion. Topical, oral, and analgesic medications are commonly used to treat osteoarthritis pain. Even if alternatives such as orthopaedic braces are used as part of a noninvasive approach to pain therapy, the adoption of pain pills for the disease is substantial due to the ease of administration and the cost of pain medications. Oral analgesics such as acetaminophen, NSAIDs, intra-articular medicines, and nutraceuticals are all common pain relievers. 

Personalised OA medications have also been proposed, which would represent a considerable advance in the diagnosis, therapy, and monitoring of disease severity in osteoarthritis patients. Simple measurement, appropriate levels of sensitivity and specificity, and test procedures available to and interpretable by clinicians are critical qualities of indicators of therapeutic relevance for a personalised approach to OA therapy. 

The use of biomarkers to identify individuals who are most likely to respond to specific medical therapies may increase treatment response rates and reduce the risk of exposing patients to medicines that are either unlikely to be effective or may cause harmful side effects from their treatment. Using a mix of unique biomarkers and baseline clinical parameters such as age and gender might be beneficial. 

Report Segmentation 

The market is primarily segmented based on treatment type, disease type, distribution channel, route of administration, and region. 

Click here for full report:

Knee Osteoarthritis segment is expected to witness fastest growth 

Personalised OA medications have also been proposed, which would represent a considerable advance in the diagnosis, therapy, and monitoring of disease severity in osteoarthritis patients. Simple measurement, appropriate levels of sensitivity and specificity, and test procedures available to and interpretable by clinicians are critical qualities of indicators of therapeutic relevance for a personalised approach to OA therapy. 

Furthermore, increased FDA approvals for the treatment of Knee OA are driving sector growth throughout the projection period. For example, Novartis announced in September 2021 that LNA043 had been granted fast-track designation by the US Food and Drug Administration (FDA) for knee osteoarthritis rehabilitation. 

Drugs targeted to treat severe diseases and address unmet medical needs can be created more swiftly and evaluated more quickly. LNA043, a possibly first-in-class disease-modifying treatment for osteoarthritis, is being developed. As a result, growing approvals for the treatment of knee OA drive market development throughout the projection period. 

Click here for free sample request:

Viscosupplementation segment industry accounted for the highest market share in 2021 

The rising prevalence of knee osteoarthritis is the key driver of this market's expansion. By injecting synovial fluid into the afflicted joints, which increases lubrication, viscosupplementation greatly lowers osteoarthritis discomfort. Furthermore, the market for viscosupplementation agents is expected to grow considerably over the forecast period due to the discovery of novel viscosupplementation agents and government efforts to boost research in the healthcare sector. 

Hospital Pharmacies are expected to hold the significant revenue share 

Hospital pharmacies retained the largest share of this market due to the large number of patients seeking treatment for osteoarthritis in hospitals and the vast assortment of osteoarthritis drugs available in these pharmacies. Another important advantage is the ease with which hospital pharmacy purchases may be reimbursed. 

The demand in North America is expected to witness significant growth 

A rise in the frequency of chronic diseases, an increase in the number of elderly people, and changes in people's lifestyles all contribute to the anticipation of market expansion in North America. As a result, the region is incorporating an increasing number of treatments and drugs. When compared to Canada and Mexico, the United States will command a substantial share of the North American market for osteoarthritis therapies. 

According to the CDC, osteoarthritis (OA), the most common kind of arthritis, is a severe chronic illness that affects 32.5 million individuals in the United States. OA is associated with ageing and is more common in those with other chronic conditions such as obesity, diabetes, and heart disease. However, 18.7 million people with OA, or more than half of them, are of working age (18 to 64 years). 

Furthermore, the availability of better treatment alternatives, government reimbursement guidelines, increased research and development activities in the creation of novel medicines, and the introduction of new therapies in the North American region are all expected to support market expansion in the region. 

Europe controlled the market for osteoarthritis therapies. The increased incidence of osteoarthritis, the ageing population, rising obesity rates in several European countries, and the growing number of sports- and accident-related injuries all contribute to this sector's large market share. 

[sam-not-sammie]

During my last therapy session, I was getting into how much being disabled has affected my mental health, and how at least soon-ish i’ll be getting a surgery that might lead to a diagnosis and treatment plan, and when I told her about the specific conditions they’re looking for, her whole face fell in empathy and sympathy for me.

She began to tell me that considering how painful those conditions were, she totally understands how stressed I’ve been.

(I then had to tell her that the surgery I’m getting won’t even address the issues at the top of my priority list, but it was nice to finally be able to get some treatment/options after about 10 years of trying to figure this out.)

It caught her so off guard, and i just kinda laughed because yeah being chronically ill and disabled is just like that!

[flamingo--ing]

ADAPTIVE WATERSKIING

[annasellheim]

Next part

[coachbeards]

im not a roy expert so idk if he would or not but…picturing roy getting a dog

[brunchbitch]

So I’ve had three PT sessions so far as sort of a tune up for my back issues. I’ve been surprised at how much weakness I have in certain muscles (especially around my hips). It feels like each time I go in, she has to make the exercises even more basic to try to limit pain. And it’s so frustrating - with my job, it’s come into even starker focus how young I am to be having these issues. I spoke to my PT about that and she was like “yes you are young, but you also have a lot going on in your back”.

Today she gave me this thick belt thing that I could wear daily to stabilize my sacroiliac joints (basically sits low on my hips). I was hoping it wasn’t what I needed bc it reminds me of back braces (though obviously much much smaller and less noticeable) but as soon as I put it on, the lower back pain on my right side disappeared. I won’t wear it to bed (whereas the back braces I would) so that’s nice, and it’s just a temporary thing while we’re focusing on strengthening the muscles around it, AND it’s amazing that something so small could help my lower back pain, but it’s still hard to come to terms with.

When I was 12 and approaching this massive life changing and life saving back surgery, the surgeon told me I would be able to do everything after the surgery that I did before, with the exception of something like gymnastics or very high impact sports like football. But I started running at age 16/17 and got a stress fracture in three vertebrae right below where the fusion ended, and since then it feels like I haven’t been without some sort of pain throughout my back/neck. I was reading back through some of my medical records and I didn’t realize that even after the fusion, my curves are still 24 and 35 degrees I think? Which would be significant curves for someone who hasn’t had surgery. My PT has told me definitively that I will need surgery to extend the fusion in my lumber/sacral joints; it’s just a matter of when. I hope to put it off for as long as possible, but it feels so defeating and scary to think of how much more my mobility will be affected. And my ED brain is definitely using this as a way to argue that I absolutely need to lose weight to support my skeletal/muscular system.

[golden-girl-daisy]

Poor Honey has arthritis in both of her shoulders even though she’s only 3. The vet suggested she try PRP therapy

[moths-in-a-coat]

having a lot of health issues (or starting to get them) at a young age sucks ngl

not just because you’re now coming to the realization that you’re reality for the rest of your life is probably going to be painful in many ways, but also because doctors just don’t believe in you or the chance there’s something wrong with you

i starting complaining of hand/arm pain when i was 13. i got diagnosed with neuropathy and chronic tendinitis last year at the age of 20

and my knee is bothering me a lot too now. it’s stiff, i can’t unbend it at times, i feel a grinding sensation when i do managed to unbend it, and i feel pain anytime i put weight on it. but i feel like my symptoms align too much with arthritis, which is an “old person” thing, so doctors are reluctant to believe there’s an actual problem outside of just “needing to exercising more.” like my knee has been bothering me for years now, but it’s just now really starting to effect how i walk

and same with the possible cancer. my endo said due to my age, it’s not too concerning that i literally have growths in my fucking neck that are growing very abnormally at a rapid rate for thyroid nodules

idk my genetics just fucking suck

[maybeamiles]

I... actually had a good experience at the doctor's today??? Wtf??? That's literally never happened since I moved here.

[foragecore]

snugglebuns

[ontherunsincenow]

This pain in my bones settles like an old friend.

It reminds of me all too much and nothing at all- I cannot stand to feel it any more.

Must I live with this?

I woke up hurting this morning.

Not moving makes it hurt- moving too much makes it hurt more.

I’m tired of waking up in pain.

It lives in my knees- Creaks in my elbows and erupts from my wrists.

It clenches my jaw and throbs behind my eyes.

Snakes up and down my spine.

Wraps greedy arms around my waist.

Clamps too firm hands on my hips.

Lays lips that burn on the back of my neck.

… He does not love me.

He drags unkind claws across my shoulders, and tears delicate skin on my chest.

Uses his mouth to bite bruises onto my legs, and his thumbs to press them onto my arms.

Pain is an unkind creature- uncaring for the damage he causes and caring only for his own satisfaction.

I'm tired of waking up to his lips on my temple.

His nails too long and teeth too sharp.

I’m tired of his hands around my throat.

Of his nails in my eyes when I cry, and his breath in my lungs when I breathe.

Allow me to exist in the correct fashion for once, won't you?

I know his answer will never be yes, but I will still ask for mercy.

Though I will not beg- no, I will never beg.

[pharmanucleus1]

Global Osteoarthritis Market, Forecast to 2030

In 2023, the worldwide osteoarthritis market was valued at USD 7.40 billion and is predicted to increase at an 8.5% CAGR during the forecast period 2023-2030. Both the introduction of analgesic drugs and the development of imaging diagnostics based on radiographic characteristics are stimulating market growth. Increased expenditure on healthcare infrastructure and expanding investments in research and development (R&D) efforts to bring novel diagnostics and biomarkers are also driving the market. 

Osteoarthritis (OA) is a group of disorders that affect the joints of the knees, hips, fingers, foot, back, shoulders, and neck. It is distinguished by the gradual degeneration of the cartilage in these joints. Stiffness, edoema, discomfort, persistent pain, loss of flexibility, a grating sensation, bone spurs, and sleep interruptions are all common symptoms of OA. 

Click here for view full report:

Medical examination, X-rays, arthroscopy, joint fluid analysis, lab testing, and magnetic resonance imaging (MRI) scans can all be used to diagnose it. Depending on the outcomes, different medications and surgical techniques are prescribed to treat the disease's signs and symptoms. There are presently alternative medicines, physical therapy, and supporting devices on the market to relieve pain and improve joint function. 

Sedentary lifestyles, poor eating habits, and increasing weight and blood sugar levels make people more susceptible to develop OA. This is one of the primary driving drivers for market development, combined with an ageing population that is more susceptible to such disorders. Furthermore, the ease of access to MRI scans is a key growth-promoting factor. 

Click here for Request free sample:

The COVID-19 outbreak is predicted to have only a minimal influence on the osteoarthritis therapy industry. Corticosteroids are being used less often in many medicine types. Although there is no evidence that corticosteroid injections significantly increase the risk of infection, the immune system may be less active for a few weeks following surgery. 

Even though the risk is extremely minimal, it should be taken into account before starting with the procedure. It should be noted that the World Health Organisation cautioned against the use of systemic corticosteroids in one of its guidelines for treating severe acute respiratory infections caused by coronavirus. 

Industry Dynamics 

Growth Drivers:  

Increased government investment on cell-based research, as well as the increasing use of opioids, are driving market expansion. Topical, oral, and analgesic medications are commonly used to treat osteoarthritis pain. Even if alternatives such as orthopaedic braces are used as part of a noninvasive approach to pain therapy, the adoption of pain pills for the disease is substantial due to the ease of administration and the cost of pain medications. Oral analgesics such as acetaminophen, NSAIDs, intra-articular medicines, and nutraceuticals are all common pain relievers. 

Personalised OA medications have also been proposed, which would represent a considerable advance in the diagnosis, therapy, and monitoring of disease severity in osteoarthritis patients. Simple measurement, appropriate levels of sensitivity and specificity, and test procedures available to and interpretable by clinicians are critical qualities of indicators of therapeutic relevance for a personalised approach to OA therapy. 

The use of biomarkers to identify individuals who are most likely to respond to specific medical therapies may increase treatment response rates and reduce the risk of exposing patients to medicines that are either unlikely to be effective or may cause harmful side effects from their treatment. Using a mix of unique biomarkers and baseline clinical parameters such as age and gender might be beneficial. 

Report Segmentation 

The market is primarily segmented based on treatment type, disease type, distribution channel, route of administration, and region. 

Knee Osteoarthritis segment is expected to witness fastest growth 

Personalised OA medications have also been proposed, which would represent a considerable advance in the diagnosis, therapy, and monitoring of disease severity in osteoarthritis patients. Simple measurement, appropriate levels of sensitivity and specificity, and test procedures available to and interpretable by clinicians are critical qualities of indicators of therapeutic relevance for a personalised approach to OA therapy. 

Click here for view full report:

Furthermore, increased FDA approvals for the treatment of Knee OA are driving sector growth throughout the projection period. For example, Novartis announced in September 2021 that LNA043 had been granted fast-track designation by the US Food and Drug Administration (FDA) for knee osteoarthritis rehabilitation. 

Drugs targeted to treat severe diseases and address unmet medical needs can be created more swiftly and evaluated more quickly. LNA043, a possibly first-in-class disease-modifying treatment for osteoarthritis, is being developed. As a result, growing approvals for the treatment of knee OA drive market development throughout the projection period. 

[dwarf-vader-of-middle-earth]

Nothing is ok. Everything's fucked. I hate being alive.

[fleshadept]

really not sure what my knee wants from me when it aches and spasms when i don't move and then does when i move "too much". but what is too much. i literally just walked to and from lunch

[bluepunkmon]

Last Trigun post for now, headcanon that due to the accelerated growth and constant damage and healing he goes through, Wolfwood's joints are absolutely fucked

[blueheartedwolf]

I wish I could find a doctor that wants to find out what’s actually wrong with me instead of recommending prescriptions to address the symptoms. I’m so tired of being recommended ibuprofen for debilitating pain. Tired of relaying my medical history to a new doctor and getting the same furrowed brow and shrugging shoulders I get every time. Tired of having so-called medical professionals ask why I need a cane if I’m able to walk down their clinic hallway without it. When will someone fucking help me?